BioNTech to pay $1.2 billion over vaccine royalties

Penn to receive $467M under settlement with BioNTech over Covid-19 vaccine royalties
Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.
BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties
BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennyslvania over the payment of royalties related to its COVID-19 vaccine,
BioNTech to pay $467M in settlement agreement with University of Pennsylvania
In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University of Pennsylvania concerning royalties and other related amounts allegedly owed on sales of the Company’s,
BioNTech to Pay Up to $1.26B in Covid-19 Vaccine Settlements With NIH, Penn
BioNTech has agreed to pay $1.26 billion across two separate settlements with the National Institutes of Health and the University of Pennsylvania tied to royalties for its Covid-19 vaccine. The German developer of RNA vaccines and immunotherapies,
BioNTech inks $1B settlements with NIH and Penn to resolve COVID vaccine royalty claims
BioNTech (NASDAQ:BNTX) announced Friday two separate agreements worth more than $1B with the National Institutes of Health (NIH) and the University of Pennsylvania to resolve royalty and other claims related to sales of its COVID-19 vaccine developed with Pfizer (PFE).
Hosted on MSN19h
BioNTech Stock In Focus After $791.5M Settlement With NIH: Retail Cautious
Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...
NIH settlement ‘manageable headwind’ for BioNTech, Pfizer, says Morgan Stanley
Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the ...
BioNTech's Big Moves: $1.2 Billion Settlements and a Game-Changing Cancer Bet
Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.
Pharmaceutical Technology5h
BNT-321 by BioNTech for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.
gulftoday1d
BioNTech settles millions’ royalty issue
Pharma majors like BioNTech in Germany and Pfizer in the United States have made profits in billions of dollars in selling ...
BioNTech SE ADR rises Friday, outperforms market
BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.
devdiscourse1d
Breakthroughs and Battles in Health: New Approvals, Lawsuits, and Discoveries
Recent health developments include the FDA's approval of an injectable version of Bristol Myers Squibb's cancer drug Opdivo.
South Korea impeaches acting president Han Duck-soo
South Korea's parliament impeached acting President Han Duck-soo on Friday, less than two weeks after suspending President ...
BioNTech SE ADR falls Thursday, underperforms market
The ADR's fall snapped a three-day winning streak.